Alto Neuroscience Inc (ANRO) ニュース

Alto Neuroscience to Participate in Upcoming Investor Conferences

– Alto to host investor day focused on ALTO-100 on September 9, 2024 – Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights

– Completed enrollment of 301 patients in Phase 2b MDD study for ALTO-100; Investor Day focused on ALTO-100 planned for September 9, 2024;...

Form 8-K - Current report

Alto Neuroscience Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision Psychiatry Approach

– $11.7 million award will be used to advance ALTO-100, a first-in-class small molecule, in a 200-patient placebo-controlled, double-blind...

Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive Disorder

– 300 patients enrolled in the study, including patients with and without the cognitive biomarker – – On track to report topline data in October...

Form 4 - Statement of changes in beneficial ownership of securities

Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia

– ALTO-101 has been shown to positively impact cognition and key cognition-related EEG markers in humans when delivered orally – – Novel...

Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner

– Dr. Etkin recognized as a Bay Area winner out of 26 finalists by an independent panel of judges – – Entrepreneur Of The Year celebrates...

Alto Neuroscience to Present at the Jefferies Global Healthcare Conference

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Company management will participate in the Jefferies Global Healthcare...

Form 8-K - Current report

Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer

– Mr. Hanley brings over two decades of leadership experience in product development and commercialization across a wide range of...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report